CLX

Business profile & competitive position

The Clorox Company operates inside the Consumer Defensive sector and the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional cleaning, food, cat litter, charcoal, water filtration, and health-and-hygiene products. Recognizable consumer brands include Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while professional sales flow through Purell, CloroxPro, and CloroxHealthcare. In fiscal 2026 the company generated roughly $6.7 billion in net sales, employed about 9,200 people, operated in approximately 25 countries, and sold into about 95 markets.

The portfolio is built around repeat-purchase household staples, and the scale implied by the revenue and brand list points to shelf-space, distribution, and consumer-habit advantages typical of this segment. That said, the margin data temper any blanket moat conclusion: Clorox’s net margin was 8.7% as of the latest snapshot. That is a positive, profitable operation, but it also signals that cost pressures, promotional spending, and commodity inputs consume most of every sales dollar. Meanwhile, ROE stands at -1,893.5%, which is not a measure of weak operating performance but rather an accounting artifact: stockholders’ equity is deeply negative, most likely the mechanical result of cumulative share buybacks, retained-deficit positioning, or long-duration liabilities. The combination of steady top-line scale, steady but not outsized profit margins, and a negative equity base suggests a company whose competitive position rests on brand power and distribution reach rather than on fortress-like capitalization.

Financial posture

Clorox’s current valuation posture can be read from a small set of concrete metrics. The stock recently traded around $83.39, giving the company a market capitalization of $10.1 billion and a trailing P/E ratio of 17.3. That multiple sits in a moderate zone for a large consumer-staples name, neither deep-value nor clearly premium. The beta of 0.57 confirms the defensive label: the stock has historically moved roughly half as much as the broader market, consistent with demand for bleach, trash bags, cat litter, and cleaning supplies that persists through most economic cycles.

Profitability is present at the operating line—the 8.7% net margin shows the business keeps some earnings after all costs—but the balance-sheet structure is unusual. A -1,893.5% ROE is mathematically driven by negative equity, so a simple “high ROE equals strong moat” reading would be misleading here. Investors looking at Clorox should treat the profitability signal and the balance-sheet signal separately: margins and cash generation matter, but the negative equity number also highlights leverage, underfunded obligations, or aggressive capital returns. The company’s 50-day EMA is $90.06, while the current price sits below that level and the RSI is 42.5, suggesting recent price momentum has been softer than the intermediate-term average.

Strategic priorities & outlook

Clorox’s most recent 10-K outlines several near-term priorities. The company is executing its IGNITE strategy, built around four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio.

Operationally, management is focused on completing and optimizing a new enterprise resource planning (ERP) system and a broader digital transformation it expects to generate long-term efficiencies across the supply chain, digital commerce, innovation, and brand-building functions. Clorox also intends to keep investing in strong brands, digital capabilities, and a streamlined operating model to build what it calls a more resilient company that can deliver consistent, profitable growth. On the portfolio front, the company is advancing its health-and-hygiene expansion, including the integration of GOJO Industries, acquired in April 2026, and growing in professional and institutional markets.

The filing also flags real headwinds. Fiscal 2026 saw declines in organic sales and earnings, with diluted EPS down 26%, partly because macroeconomic pressures and ERP transition timing had pulled some sales forward into fiscal 2025. Customer concentration is another documented risk: Walmart accounted for 26% of FY2026 net sales, and the five largest customers represented about half of consolidated net sales. Finally, the Glad bags and wraps venture with Procter & Gamble expired on January 31, 2026; Clorox purchased P&G’s 20% interest and retained core intellectual-property licenses on a royalty-free basis, giving it full control but changing the economics of that franchise.

Macro & geopolitical exposure

Because Clorox sits in the Household & Personal Products industry, its macro exposure follows the staples playbook more than the cyclical playbook. Demand for cleaning products, cat litter, trash bags, and charcoal is relatively non-discretionary, which supports stable volumes in recessions but also exposes the company to input-cost inflation in resins, chemicals, packaging materials, pulp, and energy. Freight and transportation costs matter across this sector, as do trade-policy changes that can alter tariff or duty costs on imported raw materials and finished goods.

With sales in about 95 markets and operations in roughly 25 countries, Clorox also has currency-translation exposure: a stronger U.S. dollar reduces the dollar value of overseas revenue and earnings. The category is heavily regulated around product safety, labeling, environmental standards, and chemical disclosure, so regulatory shifts can affect formulations, packaging requirements, and compliance costs. Retail concentration—already evidenced by a single customer at 26% of sales—gives large distributors pricing leverage and can compress margins during trade-promotion cycles. Private-label competition is another structural pressure common to household staples.

Recent developments

The most recent news flow has centered on Clorox’s income credentials and relative valuation rather than product launches. On October 12, 2026, fool.com published “Own Clorox by Oct. 28 to Qualify for Its Next Dividend (Yielding 6%). Here’s How Many Shares You’d Need for $5,000 in Yearly Dividends,” highlighting the stock’s indicated yield and the record-date mechanics for income-focused holders. Two days earlier, on October 10, 2026, seekingalpha.com ran “2 Dividend Kings Looking Dirt Cheap,” grouping Clorox among long-tenured dividend growers viewed as inexpensive in the current market.

On October 6, 2026, zacks.com released “Colgate vs. Clorox: Which Consumer Staples Giant Holds the Edge?,” framing the company in a head-to-head staples comparison. Separately, on October 7, 2026, prnewswire.com carried news of Calnex and VIAVI expanding a partnership on network and application performance validation; that headline is not specific to Clorox but illustrates adjacent technology-news flow that sometimes appears alongside consumer-staples coverage.

Earnings behavior & post-earnings drift

Clorox has delivered better-than-expected earnings more often than not across the last eight quarters, with a 75% beat rate (6 out of 8) and an average earnings surprise of 9.6%. The average five-day price move following those reports has been +1.67%, and the direction is classified as an upward post-earnings drift. Those averages, however, hide wide quarter-to-quarter dispersion, meaning the stock does not mechanically rise after every beat.

The four most recent reports illustrate that pattern. On August 3, 2026, Clorox earned $1.66 per share against an estimate of $1.64, a 1.2% positive surprise, and the stock rose 6.52% the next day and 9.61% over the following five days. On April 30, 2026, the company beat by 5.8% with $1.64 versus $1.55, yet it sold off 9.67% the next session and was down 4.49% over five days. The February 3, 2026 report missed by 2.8%—$1.39 against $1.43—but the stock still rose 2.43% the next day and 5.63% over five days. Finally, on November 3, 2025, a 3.9% beat with $0.85 versus $0.818 produced a modest +1.17% one-day move but a -4.08% five-day drift.

Looking ahead, Clorox is scheduled to report next on Thursday, November 3, 2026, after the market close, with the consensus EPS estimate at $1.09. That date matches the year-ago report from November 3, 2025, when Clorox beat expectations but still experienced negative drift. For traders and researchers, the key takeaway is that Clorox tends to beat estimates and shows a modest positive average drift, but the path immediately after any single report can diverge sharply from the headline surprise.

For a deeper dive into how sell-side and institutional research are currently interpreting these fundamentals, technical signals, and event risks, consider reviewing the full institutional verdict rather than relying on headline numbers alone.